SEC filings and other documents

Phase III melanoma success fuels expansion into new cancers, with scalable manufacturing and a strong vaccine portfolio.

Q2 revenue beat guidance, costs fell, and pipeline advanced; 10% growth expected in 2026.

Pipeline expansion and AI-driven innovation position the company for diversified future growth.

Growth, diversification, and pipeline innovation drive a positive financial outlook through 2028.

Intismeran plus pembrolizumab cut melanoma recurrence risk by 49% with strong safety and mechanistic proof.

AI-driven innovation and a diversified pipeline position the company for renewed growth.

2026 growth driven by ex-U.S. partnerships, new vaccines, and strong clinical data.

Up to 10% revenue growth in 2026 and EU expansion in 2027 drive breakeven by 2028.

All management proposals were approved, including director elections and auditor ratification.

Strong Q1 revenue growth and pipeline progress position the company for up to 10% growth in 2026.

Guiding up to 10% revenue growth in 2026, driven by global partnerships and pipeline progress.

Strong vaccine performance and pipeline diversification drive growth and future profitability.

Late-stage pipeline, cost discipline, and global expansion drive growth outlook through 2028.

2025 delivered cost reductions, strong cash, and pipeline momentum; 2026 targets renewed growth.

Growth shifts to new vaccines and oncology, with break-even targeted by 2028.

Seasonal vaccine growth, oncology advances, and cost discipline drive outlook for 2026-2028.